Inovio Pharmaceuticals Stock News

This move is a reversal from the day prior, which saw price move down. The post Inovio Pharmaceuticals Inc (INO): Price Up $0.1 (1.39)% Over Past Day, Up $0.06 (0.85)% Over Past Hour appeared first on ETF Daily News .

Inovio has been on a rollercoaster ride since the start of the pandemic, and its current aspirations are tied largely to the development of antiviral vaccines. With huge R&D cash burn, the stakes have

Could these top biotech stocks be worth investing in for the long term?

The company is closer than ever to launching its coronavirus vaccine -- but will it be good enough to make the stock worth purchasing?

Surmodics (NASDAQ:SRDX) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Analyst Ratings This is a breakdown of recent ratings and recommmendations for Surmodics and Inovio Pharmaceuticals, []

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given an average recommendation of Hold by the nine brokerages that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating on the company. The average 12-month target price []

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Cantor Fitzgerald boosted their FY2021 earnings per share (EPS) estimates for Inovio Pharmaceuticals in a report issued on Wednesday, November 10th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biopharmaceutical company will post earnings of ($1.24) per share for the year, up from their prior estimate of ($1.53). Cantor []

The company received a green light to begin a U.S. phase 3 study of its COVID-19 vaccine candidate.

Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Q3 2021 Results - Earnings Call Transcript

Inovio (INO) delivered earnings and revenue surprises of 12.12% and 53.68%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares are trading higher Tuesday after the FDA removed a hold on the company's late-stage COVID-19 vaccine trial in the U.S. Inovio Pharmaceuticals is tradin

The FDA lifted its hold on the next step of its COVID-19 vaccine trial, although that doesn't mean much at this point.

Inovio Pharmaceuticals (INO) stock is pushing higher on Tuesday after providing investors with an update on its Covid-19 vaccine. The post INO Stock: The Covid-19 Vaccine News Helping Inovio Power Hig

The FDA has lifted a partial clinical hold on a late-stage trial of Inovio Pharmaceuticals Inc's (NASDAQ: INO) COVID-19 vaccine in the U.S. Inovio said it now has the authorization to proceed with

Shares of Inovio Pharmaceuticals Inc. INO, +0.75% gained 5.9% in premarket trading on Tuesday after the company said it can move forward with the Phase 3 clinical trial for its experimental COVID-19 s